Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis

  • Soranna D
  • Scotti L
  • Zambon A
  • et al.
234Citations
Citations of this article
175Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Objective. Oral antidiabetic drugs (including metformin and sulfonylurea) may play a role in the relationship between type 2 diabetes and cancer. To quantify the association between metformin and sulfonylurea and the risk of cancer, we performed a meta-analysis of available studies on the issue. Materials and Methods. We performed a MEDLINE search for observational studies that investigated the risk of all cancers and specific cancer sites in relation to use of metformin and/or sulfonylurea among patients with type 2 diabetes mellitus. Fixed- and random-effect models were fitted to estimate the summary relative risk (RR). Betweenstudy heterogeneity was tested using Χ 2 statistics and measured with the I 2 statistic. Publication bias was evaluated using funnel plot and Egger's regression asymmetry test. Results. Seventeen studies satisfying inclusion criteria and including 37,632 cancers were evaluated after reviewing 401 citations. Use of metformin was associated with significantly decreased RR of all cancers (summary RR 0.61, 95% confidence interval [CI] 0.54-0.70), colorectal cancer (0.64, 95% CI 0.54 - 0.76), and pancreatic cancer (0.38, 95% CI 0.14-0.91). With the exception of colorectal cancer, significant between-study heterogeneity was observed. Evidence of publication bias for metformincancer association was also observed. There was no evidence that metformin affects the risk of breast and prostate cancers, nor that sulfonylurea affects the risk of cancer at any site. Conclusions. Metformin, but not sulfonylurea, appears to reduce subsequent cancer risk. This has relevant implications in light of the exploding global epidemic of diabetes. © AlphaMed Press.

References Powered by Scopus

Measuring inconsistency in meta-analyses

48865Citations
N/AReaders
Get full text

Bias in meta-analysis detected by a simple, graphical test

42721Citations
N/AReaders
Get full text

Meta-analysis in clinical trials

32818Citations
N/AReaders
Get full text

Cited by Powered by Scopus

Metabolism of inflammation limited by AMPK and pseudo-starvation

956Citations
N/AReaders
Get full text

Pancreatic adenocarcinoma, Version 2.2021

732Citations
N/AReaders
Get full text

AMPK, insulin resistance, and the metabolic syndrome

701Citations
N/AReaders
Get full text

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Cite

CITATION STYLE

APA

Soranna, D., Scotti, L., Zambon, A., Bosetti, C., Grassi, G., Catapano, A., … Corrao, G. (2012). Cancer Risk Associated with Use of Metformin and Sulfonylurea in Type 2 Diabetes: A Meta-Analysis. The Oncologist, 17(6), 813–822. https://doi.org/10.1634/theoncologist.2011-0462

Readers over time

‘12‘13‘14‘15‘16‘17‘18‘19‘20‘21‘22‘23‘24‘2507142128

Readers' Seniority

Tooltip

PhD / Post grad / Masters / Doc 52

55%

Researcher 28

30%

Professor / Associate Prof. 8

9%

Lecturer / Post doc 6

6%

Readers' Discipline

Tooltip

Medicine and Dentistry 70

69%

Agricultural and Biological Sciences 14

14%

Biochemistry, Genetics and Molecular Bi... 12

12%

Pharmacology, Toxicology and Pharmaceut... 5

5%

Article Metrics

Tooltip
Social Media
Shares, Likes & Comments: 40

Save time finding and organizing research with Mendeley

Sign up for free
0